Merck is pleased to announce that EMEND for oral suspension is now available.

• August 11, 2016
• Clinical Practice Updates, Drugs

Merck is pleased to announce that EMEND for oral suspension is now available.

(Click the below image to enlarge)

EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist.

EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of age and older for prevention of:

• acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin (1.1)
• nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)

Prescribing Information<http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf>

Patient Information<http://www.merck.com/product/usa/pi_circulars/e/emend/emend_ppi.pdf>

Instructions for Use<http://www.merck.com/product/usa/pi_circulars/e/emend/emend_ifu.pdf>